Cure SMA will host our first-ever Virtual Walk-n-Roll Celebration Ceremony on Saturday, May 30, 2020 at 11 a.m. EDT/10 a.m. CDT/9 a.m. MDT/8 a.m. PDT. Join us as we celebrate everything our community has achieved ...
Cure SMA has always been about creating community. During these exceptional times, we know individuals and families with SMA need us now more than ever. That is why Cure SMA is excited to ...
Dear Members of the SMA Community, In light of the COVID-19 pandemic and the burden it has placed on our healthcare system, Biogen is working with health systems, institutions, physicians, patients and their ...
Despite the new reality of quarantines, remote working, and social distancing, Cure SMA would like you to know that our work for the SMA community continues. Cure SMA remains vigilant in monitoring and ...
Cure SMA realizes that quarantining is essential for individuals and families who live with SMA, many of whom are experiencing hardships due to the COVID-19 pandemic. In response, we are pleased to launch ...
This article is the last in a series of Cure SMA grant announcements that have been shared throughout the past months. Cure SMA has awarded a $190,000 research grant to Stephen Meriney, Ph.D., ...
Dear SMA Community, As part of our ongoing partnership and following your request to receive important information about the risdiplam clinical development program, we wanted to update you on ...
Biogen today announced that the first patient has been treated in the global clinical study, DEVOTE. The study is designed to evaluate the safety, tolerability, and potential for even greater efficacy of ...
On Friday, March 27th, at 11:30am CST (9:30am PST/10:30am MST/12:30pm EST) Cure SMA will host an SMA community webinar to help answer questions and address concerns we have heard in recent days and ...
AveXis, a Novartis company, announced a one-time infusion of Zolgensma® (onasemnogene abeparvovec-xioi) showed rapid, significant, and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across a range of studies, including ...
AveXis, a Novartis company, announced that new data from the Phase 1/2 STRONG study demonstrated a one-time intrathecal (IT) administration of AVXS-101 in patients ≥2 years and <5 years of age with spinal ...
Dana Perrella is a 9-year-old on a mission to raise $50,000 for spinal muscular atrophy (SMA) research in 2020. She began baking cookies to raise money for her friend Mila, who is affected ...
